Clinical Trial Update: Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD) [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 trial evaluating Neihulizumab for standard-risk acute graft-versus-host disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Neihulizumab (neihulizumab)

Snippet

Sponsor: Sameem M. Abedin, MD | Conditions: Graft-versus-host Disease | Phase 1 | Status: COMPLETED